​
​

Centessa Pharmaceuticals (CNTA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Centessa Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$6.88M

0

Main Segment (Y)

Lixivaptan

Main Geography (Y)

Lixivaptan

Centessa Pharmaceuticals Revenue by Period

Centessa Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$6.88M100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Centessa Pharmaceuticals generated $6.88M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Centessa Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$6.91M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Centessa Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Centessa Pharmaceuticals Revenue Breakdown

Centessa Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21
Lixivaptan$200.00M

Centessa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 21: Lixivaptan (100.00%).

Centessa Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21
Lixivaptan$200.00M

Centessa Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 21: Lixivaptan (100.00%).

Centessa Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
STROSutro Biopharma$153.73M$25.71M
TRDAEntrada Therapeutics$129.01M$19.57M
GNFTGenfit$28.57M$17.08M
TARSTarsus Pharmaceuticals$17.45M$48.12M
CNTACentessa Pharmaceuticals$6.88M-
CRNXCrinetics Pharmaceuticals$4.01M-
IPSCCentury Therapeutics$2.23M$791.00K
OPTOpthea$108.41K$61.27K
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
CCCCC4 Therapeutics--
GRCLGracell Bio--
NUVLNuvalent--
IRONDisc Medicine--
ERASErasca--
MLYSMineralys Therapeutics--
LRMRLarimar Therapeutics--
HLVXHilleVax--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--

CNTA Revenue FAQ

What is Centessa Pharmaceuticals’s yearly revenue?

Centessa Pharmaceuticals's yearly revenue for 2023 was $6.88M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CNTA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is Centessa Pharmaceuticals’s quarterly revenue?

Centessa Pharmaceuticals's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). CNTA's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Centessa Pharmaceuticals’s revenue growth rate?

Centessa Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.

What are Centessa Pharmaceuticals’s revenue streams?

Centessa Pharmaceuticals's revenue streams in c 21 are Lixivaptan

What is Centessa Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Centessa Pharmaceuticals was Lixivaptan. This segment made a revenue of $200M, representing 100.00% of the company's total revenue.